Table 3.
Demographic data of recipients using different immunosuppressant regimens
| Demographic data | TAC+MMF (N=1,380) |
CsA+MMF (N=163) |
CsA+TAC+MMF (N=81) |
p-value |
|---|---|---|---|---|
| Age | 49.83 (±12.07) | 27.04 (±24.01) | 42.56 (±18.45) | <0.0001* |
| Sex | <0.0001* | |||
| Female | 375 (27.17%) | 72 (44.17%) | 25 (30.86%) | |
| Male | 1,005 (72.83%) | 91 (55.83%) | 56 (69.14%) | |
| Pre-transplant diseases | ||||
| Alcoholic hepatitis | 280 (20.29%) | 14 (8.59%) | 11 (13.58%) | 0.0007* |
| Hepatitis B | 762 (55.22%) | 42 (25.77%) | 29 (35.80%) | <0.0001* |
| Hepatitis C | 286 (20.72%) | 22 (13.5%) | 23 (28.4%) | 0.0177* |
| Esophageal varices | 735 (53.26%) | 75 (46.01%) | 36 (44.44%) | 0.0793 |
| Ascites | 699 (50.65%) | 86 (52.76%) | 40 (49.38%) | 0.8488 |
| Liver cancer | 690 (50.00%) | 30 (18.40%) | 31 (38.27%) | <0.0001* |
| Non-liver malignancy | 33 (2.39%) | 5 (3.07%) | 2 (2.47%) | 0.8705 |
| Hypertension | 237 (17.17%) | 12 (7.36%) | 12 (14.81%) | 0.0052* |
| Coronary artery disease | 88 (6.38%) | 1 (0.61%) | 3 (3.70%) | 0.0079* |
| Chronic renal failure | 44 (3.19%) | 4 (2.45%) | 1 (1.24%) | 0.5503 |
| End point | ||||
| New-onset diabetes | 127 (9.2%) | 6 (3.68%) | 23 (28.4%) | <0.0001* |
Notes: Considering pre-transplant comorbidities, liver transplant recipients of regimen TAC+MMF were of significantly older age, male sex, alcoholic hepatitis, hepatitis B, hepatitis C, liver cancer, hypertension, and coronary artery disease compared to regimen CsA+MMF. Regarding NODALT incidence, CsA+TAC+MMF regimen had the highest correlation while CsA+MMF regimen had the lowest risk. The values given for “Age” represent mean age (years) ± standard deviation;
*
p<0.05.
Abbreviations: NODALT, new-onset diabetes after liver transplantation; TAC, tacrolimus; MMF, mycophenolate mofetil; CsA, cyclosporine; DM, diabetes mellitus.